Hamburg’s Departure Hinged On Selection Of FDA Leadership Team
This article was originally published in The Gray Sheet
Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.
You may also be interested in...
In an exclusive interview with "The Gray Sheet," FDA's Deputy Commissioner Robert Califf spoke about concerns the agency has with regulating combination products, provides tips for companies looking to get combo products to market and whether he'd consider taking on the role of FDA commissioner. Listen to our exclusive podcast or read the Q&A transcript.
During her final public appearance at the National Press Club, outgoing FDA Commissioner Margaret Hamburg defended her tenure and said she was leaving a stronger FDA than the one she inherited. Asked about the agency's device regulatory process, she said she didn't know if FDA or Europe had struck the right balance but said more work needs to be done.
In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.